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80 The Journal of Thoracic and Cardiobjective: Risk algorithms were used to identify a high-risk population for trans-
atheter aortic valve implantation instead of standard aortic valve replacement in
atients with aortic stenosis. We evaluated the efficacy of these methods for
redicting outcomes in high-risk patients undergoing aortic valve replacement.
ethods: Data were collected on 638 patients identified as having isolated aortic
alve replacement between January 1, 1998 and December 31, 2006, using The
ociety of Thoracic Surgeons (STS) database. Long-term survival was determined
rom the Social Security Death Index or family contact. Operative risk was calcu-
ated using the STS Predicted Risk of Mortality, the EuroSCORE logistic and
dditive algorithms, and the Ambler Risk Score. Patients at or above the 90th
ercentile of risk (8.38% for STS, 33.47% for logistic, 12% for additive, 14.3% for
mbler) were identified as high risk. We then compared actual with predicted
ortality and each algorithm’s ability to identify patients with the worst long-term
urvival.
esults: Operative mortality was 24 of 638 (3.76%). An additional 121 (19.0%)
atients died during the follow-up study period (mean 4.2  2.7 years). Overall
ortality was 145 of 638 (22.7%). Expected versus observed mortality for the
igh-risk group by algorithm was 13.3% versus 18.8% for STS, 50.9% versus 15.6%
or logistic, 14.0% versus 11.9% for additive, and 19.0% versus 13.4% by Ambler.
ong-term mortality, per high-risk group, was 64.1% in the STS Predicted Risk of
ortality, 45.3% in the logistic, 45.2% in the additive, and 40.2% in Ambler Risk
core. Logistic regression showed that the STS algorithm was the most sensitive in
efining the patients most at risk for long-term mortality.
onclusion: The STS Predicted Risk of Mortality most accurately predicted peri-
perative and long-term mortality for the highest risk patients having aortic valve
eplacement.
ortic stenosis (AS) is the most common valvular abnormality encountered
in the United States, with a reported incidence of approximately 5 of every
10,000 adults.1 The prevalence of AS is expected to markedly increas
he US population ages, with aortic valve calcification and stenosis affecting the
ealth of larger numbers of patients.2-4
vascular Surgery ● January 2008
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ETAortic valve replacement (AVR) has been the gold stan-
ard for the treatment of critical AS for decades, and the
ndications for its implementation have been well defined in
he American College of Cardiology/American Heart Asso-
iation 2006 Practice Guidelines for the Management of
atients with Valvular Heart Disease.5
Despite unequivocal data showing the efficacy of AVR
or critical AS, there are indications that a significant num-
er of patients may not be referred for surgical therapy. A
ecent report from Varadarajan and colleagues6 from Loma
inda reported that only 287 (38%) patients of 740 with AS,
efined as a valve area of less than 0.8 cm2 by echocardi-
graphy, were referred for AVR. Additionally, the Euro
eart Survey on Valvular Heart Disease, a prospective
urvey of 5001 patients conducted at 92 centers across
urope, reported that 31.8% of patients did not undergo
urgical intervention.7 Reasons given for nonoperative ma-
gement in both studies included “old age,” severe comor-
idities, and patient refusal.
Transcatheter alternatives to standard AVR, with either
elf-expanding or balloon expandable valves, have been
eveloped to reduce the anticipated mortality and morbidity
f therapy in patients in whom the risk of conventional
urgery for critical AS was considered to be too high. Early
ublished data on procedural mortality and morbidity have
emonstrated acceptable 30-day results.8 Patients with an-
icipated diminished operative survival, and by extension
ikely reduced long-term survival, comprise a logical treat-
ent group in which to evaluate technology whose efficacy
nd in vivo durability are undetermined but offers the
hance for potential decreases in morbidity and mortality.
undamental to this process, however, is the ability to
dentify and select patients with an anticipated operative
ortality with conventional surgery that would be consid-
red prohibitive. Operative risk scoring algorithms are cur-
ently being used to identify the appropriate patient popu-
ation for transcatheter therapy. However, the accuracy of
hese risk models in identifying high-risk patients appropri-
te for nonstandard valve therapy has not been fully vali-
ated. We evaluated four common risk scoring algorithms
or their reliability in identifying high-risk patients under-
Abbreviations and Acronyms
AES  EuroSCORE additive
ARS  Ambler Risk Score
AS  aortic stenosis
AVR  aortic valve replacement
CI  confidence interval
LES  EuroSCORE logistic
STS  The Society of Thoracic Surgeons
STS-PROM STS Predicted Risk of Mortalityoing isolated AVR for critical AS based on their accuracy a
The Journal of Thoracicn predicting operative outcomes and the ability to identify
atients most likely to die during longer term follow-up.
atients and Methods
etween January 1998 and December 2006, 638 patients were
dentified as having undergone isolated AVR for critical AS. The
tudy received exempt status from the North Texas Institutional
eview Board at Medical City Dallas Hospital. The preoperative
nd perioperative data were prospectively collected and retrospec-
ively extracted from a Society of Thoracic Surgeons (STS) certi-
ed database maintained by the Cardiopulmonary Research Sci-
nce and Technology Institute, a 501C(3) medical research
rganization that collects clinical data for a 22-surgeon practice
overing 18 hospitals in the North Texas region.
The STS Predicted Risk of Mortality (STS-PROM) for aortic
alve procedures was calculated when patient data were entered
nto the STS database, whereas the EuroSCORE algorithms (lo-
istic [LES] and additive [AES]) were calculated according to
ublished guidelines (http://www.euroscore.org/). The ST
ROM uses 24 variables of more than 50 total risk factors col-
ected by the algorithm to predict mortality for valve procedures.
he LES and AES collect the same 17 variables divided into three
ategories (patient-related factors, heart-related factors, and oper-
tion-related factors) but use differing methods of weighting to
rrive at predicted risk. The AES uses an integer approach to
alculate risk, whereas the LES uses a logarithmic approach. The
mbler score was also calculated for each patient according to
reviously published guidelines.9 The Ambler Risk Score (AR
ses an integer approach with a conversion table to translate the
dditive score into a predicted risk. Patients’ risk factors are
ssigned points on the basis of 13 broad categories of preoperative
ariable ranging from age to the existence of diabetes and
ypertension.9
The 90th percentile was calculated for each scoring system and
hen patients were allocated to a “high-risk” group if their score
as at or above the 90th percentile. Inclusion into the high-risk
ohort was variable depending on the risk model used to calculate
redicted operative mortality.
Perioperative deaths (mortality within 30 days of the operation
r during the same admission) were actively tracked from the STS
atabase and late mortality was obtained by searching the Social
ecurity Death Index or through direct telephone contact.10 Long-
erm follow-up for mortality was available for all patients. All
tatistical analysis was carried out with SAS 9.1.3 software (SAS
nstitute, Inc, Cary, NC).
esults
total of 638 patients were identified as having undergone
solated AVR for critical AS between January of 1998 and
ecember of 2006. Predicted mortality for the entire group
as determined by each risk model and ranged from 4.26%
or the STS-PROM algorithm, to 7.46% for the AES, 6.99%
or the ARS, and 13.21% for the LES. Operative mortality
or the group as a whole was 24 (3.76%) of 638 patients.
atients were followed up for longer-term mortality by the
ocial Security Death Index or direct family contact. The
verage length of long-term follow-up was 4.2  2.7 years
and Cardiovascular Surgery ● Volume 135, Number 1 181
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1
ETmedian 4.11 years). During the follow-up period an addi-
ional 121 (19.0%) patients died, for an overall mortality of
45 (22.7%) of 638. Table 1 summarizes the varia
ncluded in each risk model and highlights the differences
etween each algorithm
The study population was subdivided on the basis of
ABLE 1. Risk variables used by algorithms
STS LES and AES ARS
ge X X X
ex X X X
eight X
eight X
ody mass index X
iabetes X X
hronic lung/pulmonary disease X X
xtracardiac arteriopathy X
eripheral vascular disease X
eurologic dysfunction disease X
revious cardiac surgery X
Number of previous operations X X
revious CABG X
revious valve surgery X
enal failure X X
ialysis-dependent renal failure X X
erum creatinine X X X
ypertension X X
ctive endocarditis X
Type X
erebrovascular accident X
rrhythmias X
jection fraction X
ritical preoperative state X
nstable angina X
eft ventricular dysfunction X
ecent myocardial infarct X
Timing X
ardiogenic shock X
YHA classification X
notropic agents X
ulmonary hypertension (60 mm Hg) X
Pulmonary artery mean pressure X
rocedure status X X
Emergency/emergency surgery X
ntra-aortic balloon pump timing X
ther than isolated CABG X
urgery on thoracic aorta X
itral valve surgery X X
Aortic and mitral X
oncomitant CABG surgery X
oncomitant tricuspid surgery X
ostinfarct septal rupture X
TS, The Society of Thoracic Surgeons; LES, EuroSCORE logistic; AES,
uroSCORE additive; ARS, Ambler Risk Score; CABG, coronary artery
ypass grafting; NYHA, New York Heart Association.alculated operative risk by the STS-PROM, the AES and 4
82 The Journal of Thoracic and Cardiovascular Surgery ● JanuES, and the ARS. Table 2 shows the demographic
reoperative variables of the high-risk patients as identified
y the different risk models. A high-risk cohort was defined
s those patients in the top 10% of predicted risk by each of
he four risk models (Table 3). All other patients 
esignated as low risk. The break point for the top 10% of
isk was identified by the STS-PROM as those patients
aving an operative risk greater than 8.38% and by the LES,
ES, and ARS as greater than 33.47%, 12.0%, and 14.3%,
espectively. Differences in the variables collected between
odels, and in weighting between the LES and AES algo-
ithms, resulted in different numbers of patients being iden-
ified as in the top 10% of risk per model. Additionally,
coring systems derived from integer scales (AES and ARS)
esulted in many patients with tied scores, leading to larger
umbers in the group at or above the 90th percentile as
alculated by score. The STS-PROM and LES both identi-
ed 64 patients as being in the top 10% of risk, whereas the
ES and ARS identified 83 and 97 patients, respectively.
lthough many of the same patients identified as high risk
ere included in each of the cohorts, the differences in the
ercentage of common patients further illustrates the
niqueness of each model (Figure 1). For example, w
he STS-PROM cohort was compared with the LES, only
2.5% of the patients were in both groups. Likewise, only
0.3% and 60.9% of the STS-PROM patients were also
ound in the AES and ARS, respectively, and only 4.6% (29
atients) were in the top 10% of all three scoring systems—
TS, LES, and ARS, the concordant group. By the same
isk variables, all LES patients were included in the AES
roup, but the absolute numbers identified as high risk by
ach model differed owing to the integer method used by
he AES.
Average age was 79.5  8.9 years in the STS-PROM
roup and 79.3  6.3, 78.6  7.4, and 77.3  7.7 years in
he LES, AES, and ARS groups, respectively (Table 2)
verage ejection fraction ranged from a low of 41.1% 
4.8% in the ARS cohort up to a high of 45.7%  14.6% in
he STS-PROM. Significant differences were seen between
he groups in terms of the distribution of patients with a
istory of cerebrovascular accident, peripheral vascular dis-
ase, and cerebrovascular disease. The risk variable of renal
ailure trended toward significance, with 26.6% of the STS-
ROM having this risk factor versus 20.3%, 19.1%, and
0.3% in the LES, AES, and ARS groups, respectively (P
062). There were no differences among the groups in terms
f percentage of patients having emergency procedures,
edo sternotomies, chronic pulmonary disease, New York
eart Association class III-IV heart failure, or having had a
revious myocardial infarction. Likewise, the distribution of
omen in each group was not significantly different, rang-
ng from 54.7% in the STS-PROM to 45.3%, 47%, and
6.4%, respectively, in the LES, AES, and ARS cohorts.
ary 2008
h
1
c
S
(
1
r
a
T
r
(
b
t
8
r
o
T
A
E
F
D
R
R
C
C
P
C
P
M
C
C
A
N
S
I
S
C n.
T
A
O
H
9
E
O
O
O
O
K
O
H
S
C
Dewey et al Evolving Technology
ETMean predicted operative mortality for the STS-PROM
igh-risk group was 13.31% compared with 50.87%,
4.04%, and 19.03% for the LES, AES, and ARS high-risk
ohorts, respectively (Table 3).
Measured operative mortality was 18.75% (12/64) in the
TS-PROM high-risk cohort, 15.63% (10/64) and 11.90%
10/84) in the LES and AES groups, respectively, and
3.40% (13/97) in the ARS group. The observed/expected
atios calculated for perioperative mortality were 0.31, 0.85,
ABLE 2. Preoperative demographics of high-risk patients
STS-PROM (64) %
ge (y) 79.5  8.9
jection fraction 45.7  14.6
emale gender 54.7
iabetes 42.2
enal failure 26.6
enal failure requiring dialysis 13.2
erebrovascular accident 22.2
hronic lung disease 23.1
eripheral vascular disease 34.4
erebrovascular disease 29.7
revious CABG 44.4
yocardial infarction 18.8
ongestive heart failure 75.0
ardiogenic shock 6.3
rrhythmia 35.9
YHA class (III-IV) 71.9
tatus
Elective 31.3
Emergency 1.6
Urgent 67.2
ntra-aortic balloon pump 14.1
TS-PROM, The Society of Thoracic Surgeons Predicted Risk of Mortality
ABG, coronary artery bypass grafting; NYHA, New York Heart Associatio
ABLE 3. Risk calculations and mortality rates for four ris
ll patients (638) STS-PROM
verall mean/minimum–maximum 4.26% 0.91–46.82
igh-risk groups STS-PROM (n  64)
0th percentile risk break point 8.38%
xpected (predicted) mortality in top 10%
(mean/ minimum–maximum)
13.31% 8.38%–46.8%
bserved perioperative mortality 18.75% (12/64)
bserved/expected (perioperative)
mortality
1.41
bserved late mortality 45.3% (29/64)
bserved overall mortality 64.06% (41/64)
aplan–Meier survival estimate at 5 y 38.5%  6.7%
verall mortality odds ratio, 8.06
igh/low risk group (4.63–14.01)
TS-PROM, The Society of Thoracic Surgeons Predicted Risk of Mortality
ABG, coronary artery bypass grafting; NYHA, New York Heart Association.
The Journal of Thoracicnd 0.71 in the LES, AES, and ARS cohorts, respectively.
he STS-PROM group had an observed/expected mortality
atio of 1.41. Longer-term follow-up showed that 45.3%
29/64) of the patients identified by the STS-PROM as
eing at high risk died within the follow-up period. Within
he LES and AES groups, 29.7% (19/64) and 33.3% (28/
4), respectively, of the patients identified as being at high
isk died during the follow-up period. Only 26.8% (26/97)
f the ARS patients were noted as having died. The con-
tified by various risk algorithms
(64) % AES (84) % ARS (97) % P value
 6.3 78.6  7.4 77.3  7.7 .22
 14.1 43.7  14.2 41.1  14.8 .31
5.3 47.6 46.4 .70
6.6 31.0 41.2 .13
0.3 19.1 10.3 .062
8.8 9.8 7.3 .85
8.1 28.9 13.5 .004
2.5 15.8 7.7 .82
7.5 35.7 15.5 .004
0.6 38.1 18.6 .008
7.1 51.8 41.7 .22
5.0 23.8 16.5 .49
7.2 64.3 65.0 .51
4.7 3.6 3.1 .78
2.8 32.1 42.3 .48
0.9 63.1 64.6 .33
3.1 56.0 43.3 .075
1.6 1.2 3.1
5.3 42.9 53.6
7.2 16.7 11.5 .70
, EuroSCORE logistic; AES, EuroSCORE additive; ARS, Ambler Risk Score;
gorithms
LES AES ARS
3.21% 1.51–93.32 7.46% 2–22 6.99% 0.4–39.7
LES (n  64) AES (n  84) ARS (n  97)
33.47% 12% 14.3%
7% 33.47%–93.32% 14.04% 12.0%–22.0% 19.03% 14.3%–39.7%
15.63% (10/64) 11.90% (10/84) 13.40% (13/97)
0.31 0.85 0.71
29.7% (19/64) 33.3% (28/84) 26.8% (26/97)
45.31% (29/64) 45.24% (38/84) 40.21% (39/97)
53.7%  7.2% 49.8%  6.6% 55.1%  6.2%
3.27 3.45 2.76
(1.92–5.57) (2.14–5.57) (1.75–4.36)
, EuroSCORE logistic; AES, EuroSCORE additive; ARS, Ambler Risk Score;iden
LES
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1
ETordant group showed an operative mortality of 27.6%
8/29) and long-term mortality of 34.5% (10/29) for an
verall rate of 62.1%. Overall mortality (operative plus
ollow-up deaths) was greatest in the group designated as
igh risk by the STS-PROM.
Logistic regression analysis demonstrated that the STS-
ROM had the highest odds ratio for predicting increased
verall mortality: 8.06 (95% confidence interval [CI]: 4.63–
4.01) compared with 3.27 (95% CI: 1.92–5.57) for LES,
.45 (95% CI: 2.14–5.57) for AES, and 2.76 (95% CI:
.75–4.36) for ARS when patients were identified as high
isk. A Kaplan–Meier survival curve for the four different
coring models illustrates that despite similar operative
ortality among the groups, the rate of decline for the
TS-PROM cohort, especially in the first year after the
peration, indicates a greater sensitivity in identifying pa-
ients with the worst long-term survival than the other
lgorithms (Figure 2).
iscussion
he use of risk models to standardize the prediction of
perative outcomes for patients undergoing cardiac surgery
as gained enthusiastic support over the past several years.
hese tools can provide an objective assessment of potential
ortality and morbidity for individual patients on the basis
f specific preoperative variables and aid in gaining in-
ormed consent by presenting independent corroboration of
Figure 1. Percentage of common patientshe consulting surgeon’s opinion concerning operative risk. A
84 The Journal of Thoracic and Cardiovascular Surgery ● Janueveral studies have demonstrated the accuracy of these
odels for the prediction of operative mortality.11-13 In-
reasingly, these models are also being used to identify
ppropriate patients for nonstandard or experimental ther-
py when their calculated risk profile is considered prohib-
tive with conventional approaches. The appeal of using
hese models is the ability to standardize inclusion into trials
cross many study sites, especially where surgical judgment
omes into play and may vary between centers. The STS-
ROM, EuroSCORE, and other risk models are currently
eing incorporated into various pivotal and feasibility stud-
es as part of their patient selection algorithms and inclusion
riteria. The usefulness of this approach depends on the
ccuracy of these algorithms to correctly identify the high-
st-risk patient populations. It is important to note that
odel accuracy can fluctuate over time owing to changes in
urgical risk, especially for high-risk patients, and requires
eriodic review.
In the case of transcatheter valve implantation, the risk
odels should reliably identify patients at excessive risk for
onventional AVR and the predicted mortality in that cohort
hould reasonably correlate with observed outcomes.
We compared the three most commonly used risk algo-
ithms, STS-PROM, LES, and AES, as well as a recently
ublished risk model (ARS) developed specifically for pa-
ients undergoing valvular heart surgery, for predictive abil-
ty in the highest risk decile of a cohort having isolated
hin the 90th percentile of risk by model.witVR for critical AS. A different number of patients out of
ary 2008
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Dewey et al Evolving Technology
EThe total study population were calculated to be in the top
0% of risk depending on the model used, and a sizeable
umber of patients did not overlap between the models.
tatistically, models demonstrate the most accuracy when a
ignificant percentage of the study population has a partic-
lar risk factor that is included in the risk calculation.
owever, between each risk algorithm there can exist dif-
erences in definitions and differences in actual variables
ncluded in the risk calculation, leading to different patient
tratification. For example, neurologic dysfunction in the
uroSCORE algorithm was defined to be disease that se-
erely affects ambulation or day-to-day function, whereas
he STS-PROM records only the history and timing of a
revious cerebrovascular accident. The Ambler score does
ot include neurologic dysfunction or previous cerebrovas-
ular accident in its calculation of risk of mortality. Other
otable differences between algorithms involve the inclu-
ion of New York Heart Association class, presence of
ardiogenic shock, and need for preoperative intra-aortic
alloon pump in the STS-PROM but not the AES, LES, or
he ARS. Interestingly, despite the fact that more than 50
reoperative variables are collected by the STS-PROM,
nly 24 (listed in Table 1) are actually used in its mo
lgorithm for patients having valve surgery, and preopera-
ive ejection fraction is not included in the risk model. All
odels include patient age, sex, and a measure of renal
unction through the use of serum creatinine.
The STS-PROM underpredicted but closely approached
he actual observed mortality from its identified patient
roup, with an observed/predicted ratio of 1.41. In contra-
istinction, the other three models overestimated predicted
Figure 2. Kaplan–Meier survival curves for patients inortality, and all had an observed/predicted mortality of o
The Journal of Thoracicty
ess than 1. Notably, the concordant population identified as
igh risk by all of the algorithms demonstrated not only the
ighest operative mortality (27.6%) but also the worst long-
erm survival, with an additional 10 (34.5%) of 29 dying
uring the follow-up period.
This illustrates the potential advantage of using multiple
isk algorithms with a variety of risk factors to identify a
igh-risk population. One hundred percent accuracy is an
nrealistic expectation for any single risk model for a num-
er of reasons. These models are developed using large
eterogeneous populations of patients and are derived by
eighting different risk factors on the basis of the surgical
utcomes of the whole study cohort. At the highest risk
evel, most of the patients have the same risk profiles (
), therefore providing minimal interpatient variability
hich to determine risk. This limitation in risk calculation
ay be a factor accounting for the difference between actual
isk and that predicted by each individual model. In fact,
everal studies have shown that both the LES and AES
verestimate the mortality in octogenarians undergoing val-
ular heart surgery.14,15
A further shortcoming of the models is that there are a
umber of demographic variables not collected by the risk
odels that have been shown to affect operative mortali16
ypoalbuminemia and poor nutritional status have both
een shown to be independent risk factors associated with
oor outcomes after cardiac surgery.17 In addition, Chang
nd colleagues18 have shown that patients receiving ch
all irradiation for an intrathoracic malignant tumor have
educed short- and long-term survival after cardiac surgery.
inally, frailty and debilitation are difficult conditions to
-risk groups as identified by different risk algorithms.highbjectively quantify for risk modeling and are best viewed
and Cardiovascular Surgery ● Volume 135, Number 1 185
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1
EThrough the prism of surgical judgment. It is worth empha-
izing that all risk models are derived from patients who
ave actually undergone surgery; therefore, translating
hese algorithms to populations previously never referred
or AVR may also limit their accuracy. Ultimately, the
imultaneous use of multiple models to generate a concor-
ant risk assessment will likely surpass the efficacy of any
ndividual model.
In terms of selecting patients for experimental therapies,
ome underestimation of risk represents a more conserva-
ive approach than does overprediction. Overestimation
uns the risk of potentially recruiting patients for a treatment
f unknown durability who might do well with conventional
urgery with known efficacy and long-term results. Opera-
ive mortality has historically been the most important per-
ormance parameter collected for patients having cardiac
urgery. It is an objective variable with little room for
mbiguity in data collection. However, for the elderly un-
ergoing AVR, improvement in quality of life becomes the
rimary goal of surgical intervention as opposed to extend-
ng a diminished life expectancy. Transcatheter valve im-
lantation has the potential to decrease the morbidity asso-
iated with standard AVR in a high-risk population owing
o the avoidance of a median sternotomy, cardiopulmonary
ypass, and cardioplegic arrest. Nevertheless, the selection
rocess necessitates thoughtful consideration of the short-
nd long-term risks and benefits of the procedure and a
omparison of these factors with alternative therapies. Over-
eliance on individual risk algorithms may introduce bias
wing to the limitations of the model.
In summary, the STS-PROM appears to be the most
eliable single risk scoring model of those evaluated for
oth perioperative mortality and long-term survival after
solated AVR for AS in extremely high-risk patients. Patient
dentification as high risk can differ widely between differ-
nt models on the basis of the variables collected and the
eighting used to calculate predicted mortality. Overesti-
ation of risk, especially when used to identify patients for
xperimental treatment, may lead to inclusion of patients
ho could do well with conventional approaches. Deter-
ining the appropriate break point in predicted risk that
onfers candidacy for alternative approaches can be prob-
ematic given the illustrated limitations of these four com-
only used algorithms. Surgical judgment should continue
o be used in conjunction with risk scoring to identify these
atients.
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iscussion
r Eugene H. Blackstone (Cleveland, Ohio). Dr Dewey, I con-
ratulate you and your colleagues on this particularly timely study.
ecisions are being made, at least temporarily, about appropriate
andidates for early trials of percutaneous AVR. Further, survival
fter device placement is being compared with that expected were
pen surgery performed using some of these algorithms. Your
tudy simultaneously addresses the issue of risk stratification to
dentify the highest risk patients and risk calibration to quantify
xpected risk. You paint a somewhat disturbing picture.
ary 2008
ee
m
e
t
h
e
h
q
t
i
w
r
d
w
1
t
m
a
g
s
r
r
e
e
c
(
w
(
s
r
s
y
p
t
o
T
W
d
s
t
o
d
n
a
t
a
c
b
i
a
a
c
u
u
a
o
t
c
r
r
a
m
a
r
i
a
p
p
l
d
s
t
y
a
l
f
A
G
t
w
t
v
t
p
v
o
w
p
t
w
t
h
w
b
p
s
i
w
b
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ETAs an aside, I particularly appreciate your recognizing that
arly risk does not stop at hospital discharge or even at 30 days, but
xtends further—in patients with complex problems sometimes
any months—a fact that none of these models accounts for
xplicitly.
Your study is in the same vein as the one recently presented by
he Heidelberg group at the European Association. It augments it,
owever, by looking at three algorithms for risk stratification and
xpected survival rather than just at the EuroSCORE. Let me
ighlight three findings of that group, because they lead to a
uestion about your study.
First, in the highest-risk patients, EuroSCORE greatly overes-
imated risk, just as you have found. This means that expected risk
s not well calibrated to actual risk and calls into question not just
hich patient is at high risk but also any attempt to use estimated
isk as a barometer to assess observed risk of alternative proce-
ures.
Second, they found that calibration progressively worsened
ith era of operation. The EuroSCORE was based on data from
995; 10 years later, it should not be expected to be well calibrated
o contemporary results. It needs to be updated, as do some other
easures.
But third, they nevertheless found that as a tool to rank patients
ccording to risk, that is, risk stratification, performance remained
ood.
So question one is, have you examined performance of these
cores across your experience in terms of both calibration to actual
isk and consistency in ranking patients?
Now, a different sort of observation I would like to make is
elated to what today I would call prediction error, although in
arlier times I called it residual risk. When we examined prediction
rror for time-related survival of nearly 4000 Belgian patients after
oronary artery bypass grafting, we found three categories of error:
1) variables available but ignored that actually were associated
ith risk, which is one of the points you make in your discussion;
2) variables representing rare subgroups of patients not present in
ufficient abundance at time of model development to estimate risk
eliably; and (3) variables representing subgroups completely ab-
ent from the mix of patients on whom the model was developed.
It seems that you have identified all three of these pitfalls in
our study: ignored variables, variables related to unusual com-
lexity of frail, elderly patients being considered for alternative
herapy, and a subgroup of patients not represented in the mix of
pen surgery patients for whom these models were developed.
his leads me to a second question followed by an observation:
hat was the survival of patients who were identified concor-
antly by all three algorithms and, as a corollary, what was the
urvival of the discordant patients? I ask this to encourage you not
o be terribly discouraged by somewhat discordant results by three
r four different models. Indeed, I believe this points to the correct
irection for the future.
Here is what is going on in analysis of genetic data and a
umber of other fields. Rather than developing a single model such
s a classification or risk stratification tree, thousands and even
ens of thousands of models are built from the data. Building from
single classification tree to multiple forests of trees (based
ompletely on minimizing prediction error) may pave the way for
est identifying high-risk patients and possibly even best predict- s
The Journal of Thoracicng their expected survival. But it will work only if such patients
re already present in our databases or if we become really good,
s we are not now, at extrapolating beyond our data.
Dr Dewey. Thank you very much, Dr Blackstone, for your kind
omments and for taking your time to review our manuscript. As
sual, you find a unique way of looking at the data that others of
s have not quite thought about, and I think your comments are
ctually very appropriate and cogent.
We have not examined the performance of these scores across
ur entire experience, and we have not specifically looked at how
he patients identified by each of the algorithms, how their survival
ompares with the ones who were not discordant within the algo-
ithms. One would assume that the patients in common, which
anged to about 60% for the most part, are the ones that are dying,
nd the reasons that there are differences either in perioperative
ortality or long-term follow-up is that the other risk algorithms
re diluted by other patients who do better than these truly higher-
isk patients.
Your comments in regard to updating and continually review-
ng these risk algorithms are particularly appropriate. The STS
lgorithm patient set was defined from 1994 to 1997, and our
atient population may have actually changed over that time
eriod. That is a decade ago and probably need to be updated and
ooked at to see how valid it is during this decade.
One of the tensions with these algorithms is that these are
esigned to be used at the bedside as a simple sort of tool that
urgeons can use, so that when you go into the patient’s room and
alk to the patient, you have some numbers available other than
our experience or your gestalt. And while not ever going to be as
ccurate as if you use multiple different algorithms based on much
arger data sets and variables, I think they are still relatively useful
or the tools in which we use them.
Dr Robert A. Guyton (Atlanta, Ga). That is a very nice study.
recent presentation of Core Valve patients, 22 patients from
ermany, presented an LES score averaging 11%. When we used
he STS prediction to roughly estimate this predictive mortality, it
as more in the range of 6%. The LES data appeared to overes-
imate the risk, and these were patients undergoing percutaneous
alve procedures, with a 6% to 10% operative mortality based on
hese predictions. On the basis of your study, would it be appro-
riate to recommend that patients being included in percutaneous
alve studies be assessed by more than one, perhaps at least three,
f the existing prediction systems so that we have a good idea of
hat range of operative mortality that we are talking about in these
atients who are now undergoing percutaneous or transapical
herapy?
Dr Dewey. That is a very good comment, Dr Guyton. I think I
ould be very careful about relying just on the LES, because I
hink not only our study but also other studies show that in
igh-risk patient populations it tends to overestimate risk. Now, I
ould argue that an LES of 11 is not a high-risk population to
egin with. One of the areas that we have in the percutaneous valve
atients, however, is these are typically patients who have not had
urgery, theoretically, and so how you incorporate that patient set
nto a pool of patients who had surgery in which these algorithms
ere developed is somewhat tricky. Our risk algorithms may not
e nearly as applicable to those patients who might never have had
urgery as some of the patients that we are looking at currently.
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